Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jan;104(1):829-833.
doi: 10.1007/s00277-024-06118-8. Epub 2025 Jan 23.

A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early T-precursor acute lymphoblastic leukemia/lymphoma patient

Süreyya Yiğit Kaya  1 , Mehrad Vatani  2 , Rima Akil  2 , Tansel Cakir  3 , Senem Maral  4 , Leylagül Kaynar  4 , Ömür Gökmen Sevindik  4
Affiliations
Case Reports

A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early T-precursor acute lymphoblastic leukemia/lymphoma patient

Süreyya Yiğit Kaya et al. Ann Hematol. 2025 Jan.

Abstract

Early T-precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) is a rare and aggressive subtype of T-cell leukemia with poor prognosis and resistance to standard treatments. We report a 21-year-old male with ETP-ALL/LBL who, after an initial complete remission with the HOELZER protocol, experienced early relapse and was refractory to subsequent FLEND and BFM protocols. Following disease progression and complications, he was treated with a combination of daratumumab, venetoclax, azacitidine, and dexamethasone. This regimen achieved complete remission after one cycle. This case highlights the potential of this combination therapy as an effective treatment for refractory ETP-ALL/LBL, suggesting further research is warranted to validate its efficacy and safety.

Keywords: Allogeneic hemopoietic stem cell transplantation; Azacitidine; Daratumumab, Venetoclax; Dexamethasone; Early T-precursor acute lymphoblastic leukemia/Lymphoma.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval: This article does not contain any studies with human participants or animals performed by any of the authors. Informed consent: Informed consent for publication was obtained from the patient. All the authors have reviewed the manuscript and approved it for publication. Conflict of interest: The authors declare no competing interests.

References

    1. Tarantini F, Cumbo C, Anelli L et al (2021) Inside the biology of early T-cell precursor acute lymphoblastic leukemia: the perfect trick. Biomark Res 9(1):89 - DOI - PubMed - PMC
    1. Sin Cfung (2021) Man P Hei M. Early T-Cell Precursor Acute Lymphoblastic Leukemia: diagnosis, updates in Molecular Pathogenesis, Management, and Novel therapies. Front Oncol.;11
    1. McMahon CM, Luger SM, Relapsed T, Cell ALL (2019) Current approaches and new directions. Curr Hematol Malig Rep 14(2):83–93 - DOI - PubMed
    1. Castaneda Puglianini O, Papadantonakis N (2020) Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts. Ther Adv Hematol.;11
    1. Zhang J, Ding L, Holmfeldt L et al (2012) The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481(7380):157–163 - DOI - PubMed - PMC

Publication types

MeSH terms

LinkOut - more resources